Clinical Trial

A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory autoimmune diseases.
Trial Details
NCT Number NCT07583030
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators: Nanjing Legend Biotech Co.
Conditions Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD), Progressive Multiple Sclerosis (PMS), Relapsed/Refractory Myasthenia Gravis(r/r MS)
Enrollment 44 participants
Start Date 2026-04-20
Primary Completion 2028-09-20 (estimated)
Study Completion 2041-09-20 (estimated)
Updated on ClinicalTrials.gov 2026-05-13